EMEA-002007-PIP02-17-M02

Table of contents

Key facts

Invented name
Libtayo
Active substance
Cemiplimab
Therapeutic area
Oncology
Decision number
P/0179/2022
PIP number
EMEA-002007-PIP02-17-M02
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue)
Route(s) of administration
Intravenous use
Contact for public enquiries
Regeneron Ireland DAC
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating